JavaScript seems to be disabled in your browser. You must have JavaScript enabled in your browser to utilize the functionality of this website.
Mouse
Rheumatoid synovial fluid cells and fibronectin purified human monocytes.
≥ 5.0 mg/ml
≥98% monomer by analytical SEC
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.
Functional grade preclinical antibodies are manufactured in an animal free facility using only In vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.
FC The suggested concentration for this CD64 antibody, clone 10.1, for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl or 100μl of whole blood. Titration of the reagent is recommended for optimal performance for each application.
BIHC FFFA
Clone 10.1 recognizes the alpha subunit of human FCGR1.
FCGR1 is expressed on monocytes, macrophages, dendritic cells (DCs), and activated granulocytes.
FCGR1 antibody, 10.1, recognizes high-affinity immunoglobulin gamma Fc receptor I (FCGR1), also known as CD64. FCGR1 is a 72 kDa type I transmembrane glycoprotein expressed on monocytes, macrophages, and dendritic cells (DCs). FCGR1 can also be induced on neutrophils with IFNγ and G-CSF1. FCGR1 binds with high affinity to monomeric IgG1 and IgG3, and to a lesser extent, IgG42, resulting in phosphorylation of the intracellular FCGR1 ITAM motif and subsequent recruitment of Syk. FCGR1 contributes to inflammation via several mechanisms, including promoting antibody-dependent cell-mediated cytotoxicity (ADCC), clearance of immune complexes, cytokine production, and antigen presentation1, 3. CD64-based targeted therapies eliminate M1 pro-inflammatory macrophages and show clinical potential for the treatment of macrophage-mediated chronic inflammatory diseases, such as chronic cutaneous inflammation and rheumatoid arthritis4. In addition, CD64 promotes antitumor responses and mediates cytotoxic killing of tumor cells by macrophages5.
CD64
IgG receptor
2209
UniProtKB - P12314 (FCGR1_HUMAN)
1. Hulett MD & Hogarth PM. (1998) Mol Immunol. 35(14-15):989-96 2. M. Daëron., et al. (2009) Blood. 113: 3716–37253. Alter G., et al. (2011) Epub. 415(2):160-74. Barth S., et al. (2017) Biomedicines. 5(3):565. Keler T., et al. (1998) Clin Cancer Res. 4(9):2237-43
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.
Request Data Sheet
Request product datasheet
Request safety datasheet
Delivery expected until 9/4/2025
Compare
Add to wishlist
Get an offer
Request delivery time
Ask a technical question
Submit a bulk request
sales@hoelzel.de
« Back
Subscribe, get 15% off every fifth order and have your items delivered on time!
Forgot Your Password?
Not yet registered? Create account here!